These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20090934)

  • 1. Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70.
    Banerjee Mustafi S; Chakraborty PK; Raha S
    PLoS One; 2010 Jan; 5(1):e8719. PubMed ID: 20090934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70.
    Chakraborty PK; Mustafi SB; Ganguly S; Chatterjee M; Raha S
    Cancer Sci; 2008 Jun; 99(6):1109-16. PubMed ID: 18429957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth inhibitory effect of dihydroartemisinin on Bcr/Abl+ chronic myeloid leukemia K562 cells involve AKT, ERK and NF-κB modulation.
    Lee J; Zhang G; Wu X; Xu F; Zhou J; Zhang X
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2095-102. PubMed ID: 22833150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.
    Frezzato F; Raggi F; Martini V; Severin F; Trimarco V; Visentin A; Scomazzon E; Accordi B; Bresolin S; Piazza F; Facco M; Basso G; Semenzato G; Trentin L
    Int J Cancer; 2019 Dec; 145(11):3089-3100. PubMed ID: 31044428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine].
    Sun JR; Zhang XH; He ZW; Gu Y; Yu YZ; Fang YM; Lü QH; Dong QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2246-51. PubMed ID: 17064567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
    Rahmani M; Reese E; Dai Y; Bauer C; Kramer LB; Huang M; Jove R; Dent P; Grant S
    Mol Pharmacol; 2005 Apr; 67(4):1166-76. PubMed ID: 15625278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms.
    Hirano I; Nakamura S; Yokota D; Ono T; Shigeno K; Fujisawa S; Shinjo K; Ohnishi K
    J Biol Chem; 2009 Aug; 284(33):22155-22165. PubMed ID: 19261608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
    Kawauchi K; Ogasawara T; Yasuyama M; Ohkawa Si
    Blood Cells Mol Dis; 2003; 31(1):11-7. PubMed ID: 12850478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol induces apoptosis of human chronic myelogenous leukemia cells in vitro through p38 and JNK-regulated H2AX phosphorylation.
    Wu XP; Xiong M; Xu CS; Duan LN; Dong YQ; Luo Y; Niu TH; Lu CR
    Acta Pharmacol Sin; 2015 Mar; 36(3):353-61. PubMed ID: 25619392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
    George P; Bali P; Annavarapu S; Scuto A; Fiskus W; Guo F; Sigua C; Sondarva G; Moscinski L; Atadja P; Bhalla K
    Blood; 2005 Feb; 105(4):1768-76. PubMed ID: 15514006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miRNA-301a induces apoptosis of chronic myelogenous leukemia cells by directly targeting TIMP2/ERK1/2 and AKT pathways.
    Huang X; Qi L; Lu W; Yang G; Chen Y; Zhang R; Rao J; Ji D; Huang R; Chen G
    Oncol Rep; 2017 Feb; 37(2):945-952. PubMed ID: 28035415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat stress upregulates chaperone heat shock protein 70 and antioxidant manganese superoxide dismutase through reactive oxygen species (ROS), p38MAPK, and Akt.
    Banerjee Mustafi S; Chakraborty PK; Dey RS; Raha S
    Cell Stress Chaperones; 2009 Nov; 14(6):579-89. PubMed ID: 19291423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
    Roy M; Sarkar R; Mukherjee A; Mukherjee S
    Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol Increases Anti-Proliferative Activity of Bestatin Through Downregulating P-Glycoprotein Expression Via Inhibiting PI3K/Akt/mTOR Pathway in K562/ADR Cells.
    Wang L; Wang C; Jia Y; Liu Z; Shu X; Liu K
    J Cell Biochem; 2016 May; 117(5):1233-9. PubMed ID: 26460589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
    Matsuda Y; Yamauchi T; Hosono N; Uzui K; Negoro E; Morinaga K; Nishi R; Yoshida A; Kimura S; Maekawa T; Ueda T
    Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
    Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
    Guo F; Rocha K; Bali P; Pranpat M; Fiskus W; Boyapalle S; Kumaraswamy S; Balasis M; Greedy B; Armitage ES; Lawrence N; Bhalla K
    Cancer Res; 2005 Nov; 65(22):10536-44. PubMed ID: 16288046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis.
    Ray S; Lu Y; Kaufmann SH; Gustafson WC; Karp JE; Boldogh I; Fields AP; Brasier AR
    J Biol Chem; 2004 Aug; 279(34):35604-15. PubMed ID: 15155749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.